Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis / 中华男科学杂志
National Journal of Andrology
;
(12): 982-985, 2012.
Artigo
em Chinês
| WPRIM
| ID: wpr-286405
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the efficacy of 153Sm-EDTMP in the treatment of bone metastasis of prostate cancer (PCa) by comparison with zoledronic acid.</p><p><b>METHODS</b>We assigned 55 PCa patients with bone metastasis to receive 153Sm-EDTMP (n = 31) and zoledronic acid (n = 24), the former injected intravenously at the dose of 37.0 MBq/kg body weight, and the latter administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride. We performed 99mTc-MDP bone scan before and 1 -2 months after the treatment.</p><p><b>RESULTS</b>The rate of pain relief was 83.9% in the 153Sm-EDTMP group and 58.3% in the zoledronic acid group (P = 0.035), and that of bone metabolism change was 64.5% in the former and 33.3% in the latter (P = 0.022).</p><p><b>CONCLUSION</b>153Sm-EDTMP is an ideal agent for the treatment of prostate cancer with bone metastasis.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Compostos Organometálicos
/
Compostos Organofosforados
/
Patologia
/
Neoplasias da Próstata
/
Neoplasias Ósseas
/
Usos Terapêuticos
/
Difosfonatos
/
Tratamento Farmacológico
/
Imidazóis
/
Metástase Neoplásica
Limite:
Idoso
/
Aged80
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
National Journal of Andrology
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS